TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial

Vanderstichele, Adriaan; Concin, Nicole; Busschaert, Pieter; Braicu, Ioana; Combe, Pierre; Joly, Florence; Harter, Philipp; Wimberger, Pauline; Selle, F.; Ignatov, Atanas; Schmalfeldt, Barbara; Nieuwenhuysen, Els Van; Darb‐Esfahani, Silvia; Zeimet, Alain G.; Mahner, Sven; Pujade-Lauraine, Éric; Marth, Christian; Berger, Regina; Sehouli, Jalid; Moll, Ute M.; Zeillinger, Robert; Lambrechts, Diether; Vergote, Ignace

doi:10.1136/ijgc-2019-esgo.11

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,[20][21][22][23][24][25][26] Five articles were retrospective studies, 4,21,22,24,25 and 3 articles were randomized control studies. 20,23,26 In 6 articles, the ctDNA test specimens were plasma (426 patients), 4,20,[23][24][25][26] and in 2 articles, the test specimens were serum (201 patients). 21,22 Five studies evaluated ctDNA by real-time PCR (531 patients), [20][21][22]25,26 and 3 studies evaluated ctDNA by digital PCR (96 patients).…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…20,23,26 In 6 articles, the ctDNA test specimens were plasma (426 patients), 4,20,[23][24][25][26] and in 2 articles, the test specimens were serum (201 patients). 21,22 Five studies evaluated ctDNA by real-time PCR (531 patients), [20][21][22]25,26 and 3 studies evaluated ctDNA by digital PCR (96 patients). 4,23,24 The basic characteristics of the included studies are shown in Table 5.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…All of these 8 studies discussed ctDNA and ovarian cancer FIGO staging. 4,[20][21][22][23][24][25][26] Five articles were retrospective studies, 4,21,22,24,25 and 3 articles were randomized control studies. 20,23,26 In 6 articles, the ctDNA test specimens were plasma (426 patients), 4,20,[23][24][25][26] and in 2 articles, the test specimens were serum (201 patients).…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 2 more Smart Citations

The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis

2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

Background: Studies have shown that circulating tumor DNA (ctDNA) indicates a poor prognosis in ovarian cancer. In this study, meta-analysis was used to assess the relationship between ctDNA and the prognosis of patients with epithelial ovarian cancer. Methods: The clinical trials included in this study were obtained via a search of PubMed, the Cochrane Library, the Web of Science and Embase between the period of establishment and March 2020. We selected clinical studies using qualitative or quantitative ctDNA methods to analyse the prognosis of ovarian epithelial cancer, screened the studies according to the determined inclusion and exclusion criteria, and used the modified JADAD score scale and NOS scale for evaluation, with OS (overall survival) and PFS (progression-free survival) as end events. The Cochrane Evaluation Tool was used to evaluate the quality of the randomized controlled trials. Stata 15.0 software was used to combine the effect ratio (hazard ratio, HR) and its 95% confidence interval (CI). In addition, a source analysis of ctDNA specimens, an analysis of ctDNA detection methods and a subgroup and sensitivity analysis of FIGO staging were performed. Results: A total of 8 studies were included in this meta-analysis, and ctDNA was found to be an independent risk factor for patients with epithelial ovarian cancer (OS: HR = 2.36, 95% CI [1.76,3.17], P < .001; PFS: HR = 2.51, 95% CI [1.83,3.45]). Conclusions: The results of our analysis suggested that ctDNA is a potential biomarker that can be used to evaluate the prognosis of patients with ovarian cancer.

show abstract